Effect of Vericiguat on Endpoint Events in ACS Patients With Ejection Fraction <45%：a Prospective Preventional Clinical Study
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
Investigators evaluate whether differences exsit in acute coronary syndrome（ACS） patients with ejection \<45% between participants who take vericiguat regularly and those who donot.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:
• 1.Provide written informed consent for the trial.
• 2.Has acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction \[NSTEMI\], or ST elevation myocardial infarction \[STEMI\]) or coronary revascularization (coronary artery bypass grafting \[CABG\] or percutaneous coronary intervention \[PCI\]).
• 3.ejection fraction \<45%.
• 4.Be male or female, aged greater than18 and less than 90 on the day of signing informed consent.
Locations
Other Locations
China
the First Affiliated Hospital of Nanjing Medical University
RECRUITING
Nanjing
Contact Information
Primary
LianSheng Wang
drlswang@njmu.edu.cn
13390787111
Backup
Yang Yang
273389782@qq.com
15895876832
Time Frame
Start Date: 2023-10-01
Estimated Completion Date: 2025-12-01
Participants
Target number of participants: 100
Treatments
Experimental: patients who take vericiguat
ACS patients with ejection fraction(EF)\<45% are required to take vericiguat according to the guidelines from 2.5mg once a day to 5mg after two weeks.
No_intervention: patients who donot take vericiguat
ACS patients with EF\<45% arenot required to take vericiguat.
Related Therapeutic Areas
Sponsors
Leads: The First Affiliated Hospital with Nanjing Medical University